| Title |
Combination Molecularly Targeted Drug Therapy in Metastatic Melanoma: Progress to Date
|
|---|---|
| Published in |
Drugs, May 2013
|
| DOI | 10.1007/s40265-013-0049-8 |
| Pubmed ID | |
| Authors |
Charlotte Lemech, Jeffrey Infante, Hendrik-Tobias Arkenau |
| Abstract |
Previously characterized by a median overall survival of between 6 and 12 months, metastatic melanoma now has a number of novel and effective treatment options. The ability to target the mitogen-activated protein kinase (MAPK) pathway with BRAF (v-raf murine sarcoma viral oncogene homolog B1) or MEK (mitogen-activated protein kinase kinase) inhibitors can result in rapid clinical benefit, but is too often associated with limited durability of response. Resistance inevitably develops either via reactivation of the MAPK pathway or via bypass signalling pathways, such as the PI3K (phosphoinositide 3-kinase) pathway. Combination strategies are thus appealing with an aim to overcome potential resistance mechanisms. Already, the combination of the BRAF inhibitor, dabrafenib, along with the MEK inhibitor, trametinib, has shown promising results clinically and with an improved toxicity profile. Other combination strategies with agents that target the PI3K pathway, angiogenesis, and the immune system are in development or already underway, although potential overlapping toxicities require close monitoring. The currently available molecularly targeted agents that target the MAPK pathway and development of combination therapies for treatment of metastatic melanoma are discussed in further detail. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| New Zealand | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 3% |
| Unknown | 30 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 26% |
| Student > Bachelor | 5 | 16% |
| Student > Ph. D. Student | 3 | 10% |
| Student > Master | 3 | 10% |
| Other | 2 | 6% |
| Other | 6 | 19% |
| Unknown | 4 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 48% |
| Agricultural and Biological Sciences | 5 | 16% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Social Sciences | 1 | 3% |
| Immunology and Microbiology | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 5 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 May 2013.
All research outputs
#15,271,909
of 22,710,079 outputs
Outputs from Drugs
#2,790
of 3,250 outputs
Outputs of similar age
#119,694
of 193,546 outputs
Outputs of similar age from Drugs
#25
of 34 outputs
Altmetric has tracked 22,710,079 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,250 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one is in the 10th percentile – i.e., 10% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 193,546 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.